Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Sponsor: National Cancer Institute (NCI)
This PHASE2 trial investigates Acute Myeloid Leukemia and Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 16 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Mar 2026 — Present [monthly]
Not Yet Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
▶ Show 11 earlier versions
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2022 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Oct 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.